172699-35-3

Basic information

• Product Name: 1-(2,6-dichlorophenyl)ethanaMine hydrochloride
• Synonyms: 1-(2,6-dichlorophenyl)ethanaMine hydrochloride;1-(2,6-dichlorophenyl)ethanaMine;1-(2,6-DICHLORO-PHENYL)-ETHYLAMINE;1-(2,6-Dichlorophenyl);1-(2,6-DICHLORO-PHENYL)-ETHYLAMINE HCl
• CAS NO: 172699-35-3
• Molecular Formula: C8H10Cl3N
• Molecular Weight: 226.5307
• Mol File: 172699-35-3.mol

Chemical Properties

• Boiling Point: 248.1±25.0 °C(Predicted)
• Appearance: /
• Density: 1.262±0.06 g/cm3(Predicted)
• PKA: 7.96±0.10(Predicted)
• CAS DataBase Reference: 1-(2,6-dichlorophenyl)ethanaMine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,6-dichlorophenyl)ethanaMine hydrochloride(172699-35-3)
• EPA Substance Registry System: 1-(2,6-dichlorophenyl)ethanaMine hydrochloride(172699-35-3)

Safety Data

• Hazardous Substances Data: 172699-35-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2,6-dichlorophenyl)ethanamine hydrochloride is used as a potential treatment for depression, anxiety, and other psychiatric disorders due to its ability to modulate neurotransmitter levels in the brain, which can have a positive impact on mood and overall mental well-being.
Used in Combination Therapy:
1-(2,6-dichlorophenyl)ethanamine hydrochloride is being researched for its potential to be used in combination with other drugs in the treatment of various mental health conditions, enhancing the therapeutic outcomes and addressing complex psychiatric disorders more effectively.
Used in Pain Management:
1-(2,6-dichlorophenyl)ethanaMine hydrochloride has shown promise as a potential treatment for non-psychiatric conditions such as chronic pain and neuropathic pain, indicating its potential in the field of pain management and providing relief to patients suffering from persistent or severe pain.
Overall, 1-(2,6-dichlorophenyl)ethanamine hydrochloride has demonstrated its potential as a versatile and important chemical compound in the field of pharmaceutical research and development, with applications in mental health treatment, combination therapies, and pain management.

Upstream product

• 121443-77-4 N-<(S)-1-phenylethyl>(trimethylsilyl)amine 
• 39959-67-6 1-(2-Chloro-phenyl)-ethylamine 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 20444-00-2 1,3-dichloro-2-(1-bromoethyl)benzene 
• 68285-26-7 (S)-α-(o-chlorophenyl)ethylamine 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 121443-78-5 (1S)-N-Trimethylsilyl-1-(2-chlorophenyl)ethylamine 
• 53066-19-6 1-(2',6'-dichlorophenyl)-ethanol 

Relevant articles and documents

Native Amine-Directed ortho -C-H Halogenation and Acetoxylation /Condensation of Benzylamines

Free or unfunctionalized benzylamines are well known to participate in C-H activation in the presence of palladium salts. Despite the ease with which these complexes can be activated, subsequent functionalization of the dimeric cyclometalates can be chall

N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR3), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

1-(2,6-Dichlorophenyl)ethylamine: A new and efficient chiral auxiliary for the Staudinger β-lactam synthesis

The diastereoselective synthesis of β-lactams by the Staudinger reaction was examined using chiral imines, derived from substituted 1-phenylethylamines. Among them, 1-(2,6-dichlorophenyl)ethylamine was found to be a new and efficient chiral auxiliary, and the corresponding cis-β-lactams were obtained in good to excellent yields with high diastereoselectivity.

An efficient preparation of (S)-(-)-1-(2,6-dichlorophenyl)ethylamine

(S)-(-)-1-(2,6-Dichlorophenyl)ethylamine has been prepared from (S)-α-phenethylamine in 2 steps in 44% overall yield.

Stereoselective Nucleophilic Additions to the Carbon-Nitrogen Double Bond. 2. Chiral Iminium Ions Derived from "Second Generation" Chiral Amines

"Second generation" chiral amines (1S)-(-)-1-(2-chlorophenyl)ethylamine (4) and (1S)-(-)-1-(2,6-dichlorophenyl)ethylamine (5) have been prepared from commercially available (S)-(-)-α-phenethylamine.These chiral reagents have been incorporated into chiral